In patients with non-seminomatous germ cell tumours (NSGCTs) who receive chemotherapy and have residual disease, a persistently elevated serum marker level after induction chemotherapy indicates active and progressive disease. High-dose chemotherapy (HDCT) is the standard treatment for patients with relapsed NSGCT. We present a case of a patient with residual disease from NSGCT who showed an increase in serum alpha-fetoprotein levels after HDCT, mimicking progression. Resection of the mass did not show viable cells in the tumour specimen, thus suggesting that the elevated level of the marker was expression of hepatic reconstitution after drug-induced liver damage. HDCT is increasingly used in cases of relapsed NSGCT, and the possibility of treatment-induced alpha-fetoprotein elevation must be taken into account in patient management. © 2013 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia.
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours / Luca Burgio, Salvatore; Menna, Cecilia; Papiani, Giorgio; Casadei Gardini, Andrea; De Luigi, Nicoletta; Corsi, Roberto; Rosti, Giovanni. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - 25:2(2013), pp. 119-122. [10.1179/1973947812Y.0000000044]
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours
Casadei Gardini, Andrea;
2013
Abstract
In patients with non-seminomatous germ cell tumours (NSGCTs) who receive chemotherapy and have residual disease, a persistently elevated serum marker level after induction chemotherapy indicates active and progressive disease. High-dose chemotherapy (HDCT) is the standard treatment for patients with relapsed NSGCT. We present a case of a patient with residual disease from NSGCT who showed an increase in serum alpha-fetoprotein levels after HDCT, mimicking progression. Resection of the mass did not show viable cells in the tumour specimen, thus suggesting that the elevated level of the marker was expression of hepatic reconstitution after drug-induced liver damage. HDCT is increasingly used in cases of relapsed NSGCT, and the possibility of treatment-induced alpha-fetoprotein elevation must be taken into account in patient management. © 2013 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia.File | Dimensione | Formato | |
---|---|---|---|
lucaburgio2013.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
176.81 kB
Formato
Adobe PDF
|
176.81 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris